Cilta-cel is now approved in the EU for patients with relapsed/refractory multiple myeloma previously treated with 1 or more lines of therapy. #mmsm | European Commission

cancernetwork.com/view/european-…

The FDA has granted breakthrough therapy designation to ziftomenib for those with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations. #leusm #AML | U.S. FDA FDA Oncology

cancernetwork.com/view/fda-grant…

A PDUFA date of August 23, 2024, has been set for dostarlimab plus carboplatin and paclitaxel in all adult patients with primary advanced or recurrent endometrial cancer. #gyncsm | U.S. FDA FDA Oncology

cancernetwork.com/view/dostarlim…

Gregory Charak, MD, of Hackensack Meridian addressed the rising incidence of colorectal cancer. #gicsm

cancernetwork.com/view/addressin…

#ICYMI : U.S. FDA approves lutetium Lu 177 dotatate in 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

cancernetwork.com/view/fda-appro…

Key opinion leaders discuss how bispecifics are administered at their institutions. #mmsm | Caitlin Costello, MD Matthew Pianko, MD

cancernetwork.com/view/administe…

'Adjuvant alectinib showed a significant benefit with respect to DFS as compared with chemotherapy, as well as a mainly low-grade safety profile with few discontinuations due to [AEs],” wrote Yi-Long Wu, MD. #NSCLC

cancernetwork.com/view/alectinib…

The European Commission has approved tislelizumab as a treatment for patients with NSCLC in the frontline or second-line setting. #NSCLC | European Commission Luis Paz-Ares

cancernetwork.com/view/tislelizu…

ME-344 in combination with bevacizumab showed encouraging signs of antitumor activity in patients with relapsed metastatic colorectal cancer. #gicsm

cancernetwork.com/view/me-344-be…

📺 WATCH Gregory Charak, MD, of Hackensack Meridian speak about laparoscopy or robotic tools as SOC for colorectal cancer treatment. #gicsm

cancernetwork.com/view/laparosco…

Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available. #mmsm | Caitlin Costello, MD
Matthew Pianko, MD

cancernetwork.com/view/approved-…

Administering proton therapy to pediatric populations with cancer may serve as a “great application” that helps patients avoid developing mutations and second cancers, says Timothy Chen, MD. #radonc | JTCancerCenter

cancernetwork.com/view/expert-hi…

📰 Roshni Rao, MD, FACS, reviews the KEYNOTE-522 trial findings and it's impact on #TNBC . NewYork-Presbyterian Columbia Medicine

cancernetwork.com/view/questions…

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial. #oncology #medtwitter | U.S. FDA FDA Oncology

cancernetwork.com/view/fda-appro…

“BCS followed by RT is considered standard management of patients with DCIS. However, we now realize that not all patients with DCIS will benefit from RT and there is a growing need to safely de-escalate treatment,” said Julie Margenthaler. #bcsm

cancernetwork.com/view/7-gene-pr…

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. #oncology #medtwitter | U.S. FDA FDA Oncology

cancernetwork.com/view/fda-appro…

This is the #Algorithm we have used during our discussion w/ Sam Klempner for #UpperGI
- Testing for MSI, Her 2, CPS (and soon Cldn18.2) is critical!

#OncTwitter #MedTwtitter #gism #MedEd CancerNetwork® #OncEd

.EU Medicines Agency grants ODD to annamycin for #AML treatment. #leusm

cancernetwork.com/view/annamycin…

🎙️ NEW Oncology on the Go podcast ft. Richard Lazzaro, MD, from RWJBarnabas discussing robotic-assisted biopsy in lung cancer. #lcsm

cancernetwork.com/view/moving-th…

An all-new #TreatmentAlgorithm with Oncology Brothers and Sam Klempner focusing on #gicsm . Watch now!
cancernetwork.com/treatment-algo…